Your browser doesn't support javascript.
Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection.
Landi, Doriana; Cola, Gaia; Mantero, Vittorio; Balgera, Roberto; Moiola, Lucia; Nozzolillo, Agostino; Dattola, Vincenzo; Sinisi, Leonardo; Fantozzi, Roberta; Di Lemme, Sonia; Centonze, Diego; Mataluni, Giorgia; Nicoletti, Carolina Gabri; Marfia, Girolama Alessandra.
  • Landi D; University of Rome Tor Vergata, Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Roma, Italy.
  • Cola G; University of Rome Tor Vergata, Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Roma, Italy.
  • Mantero V; ASST Lecco, MS Center, Lecco, Italy.
  • Balgera R; ASST Lecco, MS Center, Lecco, Italy.
  • Moiola L; San Raffaele Hospital IRCCS, Multiple sclerosis center-Neurology Department, Milano, Italy.
  • Nozzolillo A; San Raffaele Hospital IRCCS, Multiple sclerosis center-Neurology Department, Milano, Italy.
  • Dattola V; Grande Ospedale Metropolitano Bianchi Melacrino Morelli, UOC Neurologia, Reggio Calabria, Italy.
  • Sinisi L; San Paolo Hospital ASL Napoli 1 Centro, Neurology Unit and MS Center, Napoli, Italy.
  • Fantozzi R; IRCCS Neuromed, Unit of Neurology, Pozzilli (IS), Italy.
  • Di Lemme S; IRCCS Neuromed, Unit of Neurology, Pozzilli (IS), Italy.
  • Centonze D; IRCCS Neuromed, Unit of Neurology, Pozzilli (IS), Italy; University of Rome Tor Vergata, Department of Systems Medicine, Roma, Italy.
  • Mataluni G; University of Rome Tor Vergata, Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Roma, Italy.
  • Nicoletti CG; University of Rome Tor Vergata, Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Roma, Italy.
  • Marfia GA; University of Rome Tor Vergata, Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Roma, Italy; IRCCS Neuromed, Unit of Neurology, Pozzilli (IS), Italy.
Mult Scler Relat Disord ; 57: 103345, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-1851824
ABSTRACT
COVID-19 pandemic represented a challenge in the management of treatments for Multiple Sclerosis (MS), such as Natalizumab (NTZ). NTZ interferes with the homing of lymphocytes into the central nervous system, reducing immune surveillance against opportunistic infection. Although NTZ efficacy starts to decline 8 weeks after the last infusion, increasing the risk of disease reactivation, evidence is lacking on the safety of reinfusion during active SARS-CoV-2 infection. We report clinical outcomes of 18 pwMS receiving NTZ retreatment during confirmed SARS-CoV-2 infection. No worsening of infection or recovery delay was observed. Our data supports the safety of NTZ redosing in these circumstances.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / COVID-19 / Multiple Sclerosis Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2022 Document Type: Article Affiliation country: J.msard.2021.103345

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / COVID-19 / Multiple Sclerosis Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2022 Document Type: Article Affiliation country: J.msard.2021.103345